Anti-phosphatidylserine/prothrombin antibodies in patients with polyarteritis nodosa.
Anti-fosfatidilserina/protrombina
Anti-phospatidylserine/prothrombin
Anti-phospholipid antibodies
Anticuerpos antifosfolípidos
Poliarteritis nodosa
Polyarteritis nodosa
Vasculitis
Journal
Reumatologia clinica
ISSN: 2173-5743
Titre abrégé: Reumatol Clin (Engl Ed)
Pays: Spain
ID NLM: 101717526
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
12
05
2020
accepted:
27
05
2020
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Anti-phospatidylserine/prothrombin (aPS/PT) antibodies have been described in cutaneous Polyarteritis Nodosa (PAN) in association with specific manifestations. To determine aPS/PT antibodies in patients with PAN and its correlation with clinical manifestations. Cross-sectional comparative study including PAN patients and 20 controls (10 Microscopic Polyangiitis [MPA] and 10 Behçet's disease [BD]). Clinical and demographic variables, treatment, serologic markers, prognosis, activity and damage indexes were evaluated. aPS/PT, anti-cardiolipin (aCL), anti-beta 2 glycoprotein 1 (anti-B2GP1) antibodies, and lupus anticoagulant (LA) were determined. Fourteen patients with PAN were included, 11 (79%) women, with disease duration of 207 months, and mostly inactive disease. Only one patient with PAN and one with BD were positive for aPS/PT IgG. LA was the most frequent antibody identified. One patient with MPA and one with BD were positive for aCL IgM; one with MPA for anti-B2GP1 IgG, and one with PAN for anti-B2GP1 IgM. aPS/PT antibodies are not frequent in patients with longstanding inactive PAN.
Identifiants
pubmed: 34756313
pii: S2173-5743(21)00019-8
doi: 10.1016/j.reumae.2020.05.005
pii:
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Phosphatidylserines
0
Prothrombin
9001-26-7
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-524Informations de copyright
Copyright © 2020 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.